Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Diabetologia
Published in: Diabetologia 10/2006

01-10-2006 | Article

Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes

Authors: Y. Yu, S. R. Thorpe, A. J. Jenkins, J. N. Shaw, M. A. Sochaski, D. McGee, C. E. Aston, T. J. Orchard, N. Silvers, Y. G. Peng, J. A. McKnight, J. W. Baynes, T. J. Lyons, The DCCT/EDIC Research Group

Published in: Diabetologia | Issue 10/2006

Login to get access

Abstract

Aims/hypothesis

We determined whether oxidative damage in collagen is increased in (1) patients with diabetes; (2) patients with diabetic complications; and (3) subjects from the Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) study, with comparison of subjects from the former standard vs intensive treatment groups 4 years after DCCT completion.

Subjects, materials and methods

We quantified the early glycation product fructose-lysine, the two AGEs N ε-(carboxymethyl)lysine (CML) and pentosidine, and the oxidised amino acid methionine sulphoxide (MetSO) in skin collagen from 96 patients with type 1 diabetes (taken from three groups: DCCT/EDIC patients and clinic patients from South Carolina and Scotland) and from 78 healthy subjects.

Results

Fructose-lysine was increased in diabetic patients (p<0.0001), both with or without complications (p<0.0001). Controlling for HbA1c, rates of accumulation of AGEs were higher in diabetic patients than control subjects, regardless of whether the former had complications (CML and pentosidine given as loge[pentosidine]) or not (CML only) (all p<0.0001). MetSO (loge[MetSO]) also accumulated more rapidly in diabetic patients with complications than in controls (p<0.0001), but rates were similar in patients without complications and controls. For all three products, rates of accumulation with age were significantly higher in diabetic patients with complications than in those without (all p<0.0001). At 4 years after the end of the DCCT, no differences were found between the previous DCCT management groups for fructose-lysine, AGEs or MetSO.

Conclusions/interpretation

The findings suggest that in type 1 diabetic patients enhanced oxidative damage to collagen is associated with the presence of vascular complications.
Literature
1.
Lyons TJ (2002) Glycation, carbonyl stress, EAGLEs, and the vascular complications of diabetes. Semin Vasc Med 2:175–189PubMedCrossRef
2.
Thorpe SR, Lyons TJ, Baynes JW (2000) Glycation and glycoxidation in diabetic vascular disease. In: Keaney JF (ed) Oxidative stress and vascular disease. Kluwer, Norwell, pp 259–283
3.
Fu MX, Requena JR, Jenkins AJ, Lyons TJ, Baynes JW, Thorpe SR (1996) The advanced glycation end-product, N ε-(carboxymethyl)lysine, is a product of both lipid peroxidation and glycoxidation reactions. J Biol Chem 271:9982–9986PubMedCrossRef
4.
Kasper M, Schieberle P (2005) Labeling studies on the formation pathway of N ε-carboxymethyllysine in Maillard-type reactions. Ann N Y Acad Sci 1043:59–62PubMedCrossRef
5.
Lyons TJ, Bailie KE, Dyer DG, Dunn JA, Baynes JW (1991) Decrease in skin collagen glycation with improved glycaemic control in patients with insulin-dependent diabetes mellitus. J Clin Invest 87:1910–1915PubMed
6.
Dyer DG, Dunn JA, Thorpe SR et al (1993) Accumulation of Maillard reaction products in skin collagen in diabetes and aging. J Clin Invest 9:2463–2469
7.
Sell DR, Lapolla A, Odetti P, Fogarty J, Monnier VM (1992) Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM. Diabetes 41:1286–1292PubMedCrossRef
8.
Beisswenger PJ, Moore LL, Brinck-Johnsen T, Curphey TJ (1993) Increased collagen-linked pentosidine levels and advanced glycosylation end products in early diabetic nephropathy. J Clin Invest 92:212–217PubMed
9.
Beisswenger PJ, Moore LL, Curuphey TJ (1993) Relationship between glycaemic control and collagen-linked advanced glycation end products in type 1 diabetes. Diabetes Care 16:689–694PubMedCrossRef
10.
McCance DR, Dyer DG, Dunn JA et al (1993) Maillard reaction products and their relation to the complications of diabetes. J Clin Invest 9:2470–2478CrossRef
11.
Onorato JM, Thorpe SR, Baynes JW (1998) Immunohistochemical and ELISA assays for biomarkers of oxidative stress in aging and disease. Ann N Y Acad Sci 854:277–290PubMedCrossRef
12.
Wells-Knecht MC, Lyons TJ, McCance DR, Thorpe SR, Baynes JW (1997) Age-dependent accumulation of ortho-tyrosine and methionine sulfoxide in human skin collagen is not increased in diabetes: evidence against a generalised increase in oxidative stress in diabetes. J Clin Invest 100:839–846PubMed
13.
The Diabetes Care and Complications Trial (DCCT) (1993) The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977–986CrossRef
14.
Epidemiology of Diabetes Interventions and Complications (EDIC) (1999) Design, implementation, and preliminary results of a long-term follow-up of the Diabetes Control and Complications Trial cohort. Diabetes Care 22:99–111CrossRef
15.
The Diabetes Control and Complications Trial (DCCT) Research Group (1995) The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. Arch Ophthalmol 113:36–51
16.
Jenkins AJ, Lyons TJ, Zheng D et al (2003) Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. Diabetes Care 26:810–818PubMedCrossRef
17.
Dunn, JA, McCance, DR, Thorpe, SR, Lyons, TJ, Baynes, JW (1991) Age-dependent accumulation of N ε-(carboxymethyl)-lysine and N ε-(carboxymethyl)-hydroxylysine in human skin collagen. Biochemistry 30:1205–1210PubMedCrossRef
18.
Dyer DG, Blackledge JA, Thorpe SR Baynes JW (1991) Formation of pentosidine during nonenzymatic browning of proteins by glucose: identification of glucose and other carbohydrates as possible precursors of pentosidine in vivo. J Biol Chem 266:11654–11660PubMed
19.
Sochaski MA, Jenkins AJ, Lyons TJ, Thorpe SR, Baynes JW (2001) Isotope dilution gas chromatography/mass spectrometry method for the determination of methionine sulfoxide in protein. Anal Chem 73:4662–4667PubMedCrossRef
20.
The Diabetes Care and Complications Trial (DCCT) (1987) Feasibility study. Diabetes Care 10:1–19CrossRef
21.
Monnier VM, Bautista O, Kenny DR, et al (1999) Skin collagen glycation, glycoxidation, and crosslinking are lower in subjects with long-term intensive vs conventional therapy of type 1 diabetes: relevance of glycated collagen products vs HbA1c as markers of diabetic complications. Diabetes 48:870–880PubMedCrossRef
22.
Genuth S, Sun W, Cleary P, et al (2005) Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in DCCT/EDIC participants with type 1 diabetes. Diabetes 54:3103–3111PubMedCrossRef
23.
Ahmed MU, Frye EB, Degenhardt TP, Thorpe SR, Baynes JW (1997) N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 324:565–670PubMed
24.
Degenhardt TP, Thorpe SR, Baynes JW (1998) Chemical modification of proteins by methylglyoxal. Cell Mol Biol 44:1139–1145PubMed
25.
Szwergold BS, Beisswenger PJ (2003) Enzymatic deglycation—a new paradigm or an epiphenomenon? Biochem Soc Trans 31:1428–1432PubMedCrossRef
26.
Hoshi T, Heinemann S (2001) Regulation of cell function by methionine oxidation and reduction. J Physiol 531:1–11PubMedCrossRef
27.
Schulze PC, Yoshioka J, Takahashi T, He Z, King GL, Lee RT (2004) Hyperglycaemia promotes oxidative stress through inhibition of thioredoxin function by thioredoxin-interacting protein. J Biol Chem 279:30369–30374PubMedCrossRef
28.
Kobayashi T, Uehara S, Ikeda T, Itadani H, Kotani H (2003) Vitamin D3 up-regulated protein-1 regulates collagen expression in mesangial cells. Kidney Int 64:1632–1642PubMedCrossRef
29.
Chopra M, Beswick H, Clapperton M, Dargie HJ, Smith WE, McMurray J (1992) Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol 19:330–340PubMedCrossRef
30.
Miyata T, van Ypersele de Strihou C, Ueda Y, et al (2002) Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 13:2478–2487PubMedCrossRef
31.
Akira K, Amano M, Okajima F, Hashimoto T, Oikawa S (2006) Inhibitory effects of amlodipine and fluvastatin on the deposition of advanced glycation end products in aortic wall of cholesterol and fructose-fed rabbits. Biol Pharm Bull 29:75–81PubMedCrossRef
32.
Ng DS (2005) The role of statins in oxidative stress and cardiovascular disease. Curr Drug Targets Cardiovasc Haematol Disord 5:165–175PubMedCrossRef
33.
Brownlee M (2001) Biochemistry and molecular cell biology of diabetic complications. Nature 414:813–820PubMedCrossRef
34.
Pennathur S, Ido Y, Heller JI et al (2005) Reactive carbonyls and polyunsaturated fatty acids produce a hydroxyl radical-like species: a potential pathway for oxidative damage of retinal proteins in diabetes. J Biol Chem 280:22706–22714PubMedCrossRef
Metadata
Title
Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes
Authors
Y. Yu
S. R. Thorpe
A. J. Jenkins
J. N. Shaw
M. A. Sochaski
D. McGee
C. E. Aston
T. J. Orchard
N. Silvers
Y. G. Peng
J. A. McKnight
J. W. Baynes
T. J. Lyons
The DCCT/EDIC Research Group
Publication date
01-10-2006
Publisher
Springer-Verlag
Published in
Diabetologia / Issue 10/2006
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-006-0355-8

Other articles of this Issue 10/2006

Diabetologia 10/2006 Go to the issue

Article

PPARγ agonism increases rat adipose tissue lipolysis, expression of glyceride lipases, and the response of lipolysis to hormonal control

Short Communication

The apolipoprotein A-V genotype and plasma apolipoprotein A-V and triglyceride levels: prospective risk of type 2 diabetes. Results from the Northwick Park Heart Study II

Short Communication

A perfusion protocol for highly efficient transduction of intact pancreatic islets of Langerhans

Article

Naphthalenemethyl ester derivative of dihydroxyhydrocinnamic acid, a component of cinnamon, increases glucose disposal by enhancing translocation of glucose transporter 4

Article

BCL-6: a possible missing link for anti-inflammatory PPAR-δ signalling in pancreatic beta cells

Article

Peroxisome proliferator-activated receptor-γ coactivator-1 and insulin resistance: acute effect of fatty acids
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits